Choose your preferred way to stay informed of new case launches and settlement deadlines
On May 1, 2025, Eli Lilly issued a press release reporting first quarter 2025 results and reaffirming guidance. In conjunction with this press release, Eli Lilly management commented on the decision made by CVS, one of the country’s largest pharmacies, to drop coverage for its popular weight-loss drug, Zepbound, in favor of competitor’s Wegovy. Notably, Eli Lilly’s CEO attributes 45% of the Company’s year-over-year revenue growth to strong sales of Zepbound and Mounjaro. Following this news, Eli Lilly’s stock price fell by $104.85 per share, or approximately 11.7% to close at $794.10 per share.
In order to be eligible to join the LLY class action lawsuit, you must have incurred a loss on shares of Eli Lilly purchased during the class period listed above.
TOP
